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Plterations in Myocardial Tissue Factor Expression
nd Cellular Localization in Dilated Cardiomyopathy
jörn Szotowski, MPHARM,*† Petra Goldin-Lang, PHD,* Silvio Antoniak, MS,*
ladimir Y. Bogdanov, PHD,‡ Delano Pathirana,* Matthias Pauschinger, MD,* Andrea Dörner, PHD,*
we Kuehl, PHD,* Sarah Coupland, MD,§ Yale Nemerson, MD,‡ Michael Hummel, MD,§
olfgang Poller, MD,* Roland Hetzer, MD, PHD, Heinz-Peter Schultheiss, MD,* Ursula Rauch, MD*
erlin, Germany; and New York, New York
OBJECTIVES We investigated the myocardial localization and expression of tissue factor (TF) and
alternatively spliced human tissue factor (asHTF) in patients with dilated cardiomyopathy
(DCM).
BACKGROUND Tissue factor is expressed in cardiac muscle and may play a role in maintaining myocardial
structure.
METHODS Myocardial biopsies were obtained from patients with a normal or mildly impaired ejection
fraction (EF) (50%) and moderate to severely reduced EF (50%). Explanted DCM hearts
were also examined. Myocardial TF expression level was assessed by real-time polymerase
chain reaction, TF protein by enzyme-linked immunosorbent assay, and localization by
immunohistochemistry.
RESULTS We report the identification of asHTF in the human myocardium: it was located in
cardiomyocytes and endothelial cells. Quantification of myocardial TF messenger ribonucleic
acid in DCM revealed a decrease in the TF/glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) ratio (1.76  101  6.08  102 for EF 50% [n  19] vs. 1.06  101 
5.26  102 for EF 50% [n  27]; p  0.001) and asHTF/GAPDH ratio (13.91  105
 11.20  105 for EF 50% vs. 7.17  105  3.82  105 for EF 50%; p  0.014).
Tissue factor isoform expression level was also decreased in explanted DCM hearts (p 0.01;
n  12). Total TF protein was reduced by 26% in DCM (p  0.05). The TF/GAPDH ratio
correlated positively with the EF (r  0.504, p  0.0001). Immunohistochemistry showed
TF localized to the sarcolemma and Z-bands of the cardiomyocytes in patients with normal
EF, whereas TF was found in the cardiomyocytic cytosol around the nucleus in DCM.
CONCLUSIONS Tissue factor was down-regulated in the myocardium of DCM patients. The reduction in TF
expression and change in localization may influence cell-to-cell contact stability and
contractility, thereby contributing to cardiac dysfunction in DCM. (J Am Coll Cardiol
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.12.0612005;45:1081–9) © 2005 by the American College of Cardiology Foundation
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vissue factor (TF), the primary initiator of the extrinsic
oagulation cascade, is a 263 amino acid transmembrane
rotein, which is the cellular receptor for factor VII (1–3).
eyond its role in hemostasis, TF is abundantly expressed
y cardiomyocytes in the human heart but not in skeletal
uscle (4,5). In the adult heart, TF is present in the
ransverse part of the intercalated disk and co-localizes with
he cytoskeletal proteins desmin and vinculin (4). The
ytoplasmic domain of TF interacts with actin-binding
rotein 280 (filamin), thereby influencing adhesion and
igration of cells (6). The myocardial TF expression was
ound to correlate with the number of contact sites of
ardiomyocytes, pointing to an important role of TF for
aintaining the structural integrity and contractility of the
yocardial muscle (4,5). In patients with hypertension and
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Manuscript received September 13, 2004; revised manuscript received November
9, 2004, accepted December 6, 2004.entricular hypertrophy, the TF level was found to be
educed in structurally altered ventricular myocardium (4).
n addition, a complete TF knockout in the murine 129/Sv
enetic background leads to TF null embryos that do not
urvive beyond mid-gestation (7). Defects in cytoskeletal
nd junctional proteins in dilated cardiomyopathy (DCM)
re known to contribute to cardiac dilation and dysfunction
8). Whether alterations in the myocardial TF expression
lso occur in the cardiac muscle of patients with DCM has
ot been examined to date. However, mice expressing low
evels of human TF showed a myocardial defect with
yocardial fibrosis, hemosiderin deposition, and ventricular
ysfunction (9). In addition, alternative splicing of the TF
re-messenger ribonucleic acid (mRNA) leads to the gen-
ration of a soluble TF isoform (asHTF), which has recently
een detected in the circulating blood (10). Leukocytic cells
ave been suggested to be the source of TF and asHTF in
lood (10). Stimulated endothelial cells also express TF
RNA isoforms (11) and therefore may contribute to
sHTF in blood as well. Growth factors and cytokines are
nown to induce the TF expression in a variety of cardio-
ascular cells (11–13). Moreover, cytokines may also con-
ribute to the development of DCM (14). Whether asHTF
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Altered TF Expression in Cardiomyopathy April 5, 2005:1081–9s constitutively expressed in the human myocardium is
nknown. Therefore, we examined the expression and
ocalization of TF and its soluble isoform in the cardiac
issue of patients with a normal ejection fraction (EF) and of
atients with DCM.
ATERIALS AND METHODS
tudy design. Myocardial biopsies of 79 patients with the
resumptive clinical diagnosis of cardiomyopathy and ven-
ricular tissue from 12 explanted DCM hearts were exam-
ned. Tissue specimens were taken from the right ventricular
eptum and immediately frozen in liquid nitrogen in order
o preserve RNA and protein content. Coronary angiogra-
hy was performed in all patients to rule out coronary artery
isease. The presence of valvular heart disease, amyloidosis,
r other accumulation disease was also excluded. According
o the 1995 World Health Organization/International So-
iety and Federation of Cardiology report on the definition
nd classification of cardiomyopathies, 79 biopsied patients
ere divided into two groups dependent on the EF mea-
ured during left ventricular catheterization: 37 patients had
ormal to mildly reduced EF (50%) and 42 patients
oderate to severely reduced EF (50%). The patients
ith normal EF had loco-regional wall motion disturbances
n at least two different wall segments on echocardiography
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
asHTF  alternatively spliced human tissue factor
DCM  dilated cardiomyopathy
DNA  deoxyribonucleic acid
EF  ejection fraction
ELISA  enzyme-linked immunosorbent assay
mRNA  messenger ribonucleic acid
PCR  polymerase chain reaction
TF  tissue factor
able 1. Primer and Probe Sequences
A. Primer Sequences Used for Convention
Forward Primer
=-CGCCGCCAACTGGTAGAC 5=-TG
B. Primer Sequences
Forward Primer
F 5=-TGATGTGGATAAAGGAGAAAACTACT
sHTF 5=-GGGATGTTTTTGGCAAGGACTTA
APDH 5=-CCACCCATGGCAAATTCC
C. Probe Sequences
F 5=-FAM-TTC
sHTF 5=-FAM-AAT
APDH 5=-FAM-TGGarentheses: amplicon size of asHTF.
asHTF  alternatively spliced human tissue factor; GAPDH  glyceraldehyde-3-phosnd/or had clinical symptoms such as unexplained chest
ain or heart rhythm disturbances. Ventricular septum of
xplanted hearts from patients with DCM and severely
mpaired myocardial function was also examined in a
eparate group (n  12). To keep the amount of myocardial
iopsies as low as possible and to avoid unnecessary risks for
he patients, either TF mRNA or protein levels were
etermined from a myocardial biopsy. To assess the impact
f cardiomyopathy on TF expression, mRNA levels were
uantified by real-time polymerase chain reaction (PCR) in
6 of 79 biopsied patients (n  27 with an EF 50% and
 19 with an EF 50%) and in the explanted hearts (n
12). The content of TF protein in myocardial biopsies
as measured by TF enzyme-linked immunosorbent assay
ELISA) in 33 of the 79 biopsied patients (n  15 with an
F 50% and n  18 with an EF 50%). Immunohisto-
hemistry was performed to visualize TF protein and
ocalization within the myocardial tissues. All procedures
ere approved by our institutional review board and per-
ormed in accordance with ethical standards and the Hel-
inki Declaration of 1975. All patients gave informed
onsent for the study.
everse transcription-PCR (RT-PCR). Total RNA of
uman heart biopsies was isolated by the TRIzol method
ccording to manufacturer’s instruction (Invitrogen,
arlsruhe, Germany), reverse transcribed, and analyzed by
CR using primers listed in Table 1A. Products were
eparated by electrophoresis on 1% agarose, visualized with
thidium bromide under ultraviolet light, and bands were
xcised. To ensure that the products obtained by transcrip-
ion represented TF isoform sequences, full-length TF as
ell as asHTF (Gene Bank accession number AF 487337)
pecific sequences were verified by direct sequencing of the
CR products. Conventional PCR was performed under
he following conditions: 94°C, 2 min; 94°C, 15 s; 64°C,
0 s; 68°C, 1 min for 30 cycles.
eal-Time PCR Detecting TF and asHTF
Reverse Primer Product (bp)
TAGCTCCAACAGTGC 931 (771)
for Real-Time PCR
Reverse Primer Product (bp)
5=-CTACCGGGCTGTCTGTACTCTTC 92
5=-CCAGGATGATGACAAGGATGATG 124
5=-TCGCTCCTGGAAGATGGTG 89
for Real-Time PCR
Probe
CAGTGATTCCCTCCCGAACA-TAMRA
CAAGTTCAGGAAAGAAATATTCTACATCATTGGA-TAMRA
CGTCAAGGCTGAGAACGT-TAMRAal R
CAG
Used
GT
Used
AAG
CTT
CACphate dehydrogenase; PCR  polymerase chain reaction; TF  tissue factor.
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April 5, 2005:1081–9 Altered TF Expression in CardiomyopathyF isoform specific real-time PCR (TaqMan). Total
NA was isolated as described previously. First, 0.5 g total
NA of each sample was transcribed into complementary
eoxyribonucleic acid (DNA) by using avian mycoblastosis
irus reverse transcriptase (AMV RT) and random hexamer
rimers according to the supplier’s instructions (Roche
pplied Sciences, Mannheim, Germany). Then, 3 l of
ach complementary DNA preparation was diluted to a
nal PCR volume of 25 l containing 12.5 l TaqMan
niversal Master Mix (Applied Biosystems, Foster City,
alifornia), and 0.25 l (200 nM) primers (TIB Molbiol,
erlin, Germany) and 0.3 l (100 nM) probes as listed in
ables 1B and 1C. Each sample was tested for the following
RNAs: TF, asHTF, and GAPDH. In order to differen-
iate between TF and asHTF, primers and probe for
etection of TF have been positioned in exon 5, which is
issing in asHTF, whereas asHTF primers have been
ositioned in exon 4 and 6, respectively, with the probe
panning exon 4/6 boundary, which is not present in TF.
eal-time PCR was performed using ABI Prism 7000
equence Detection System (Applied Biosystems) under the
ollowing conditions: 50°C, 2 min; 95°C, 10 min; 40 cycles
5°C, 15 s, 60°C, 1 min. Standards covering the complete
oding sequence for each target were generated by RT-
CR. Serial dilutions of each standard were made.
mmunohistochemistry. For TF and asHTF staining,
pecimens were immediately snap-frozen and stored at
80°C. Cryostat sections were washed with phosphate-
uffered saline, incubated in 4% H2O2, and immunostained
ither with polyclonal goat anti-human antibody against TF
American Diagnostica Inc., Stamford, Connecticut), di-
uted 1:200 in phosphate-buffered saline/fetal calf serum, or
ith polyclonal rabbit anti-human antibody against asHTF,
espectively. Polyclonal asHTF antibodies were raised
gainst the last 29 amino acids of the unique C-terminal
sHTF domain, conjugated to keyhole limpet hemocyanin
Pineda Antikörper-Service, Berlin, Germany). A second
olyclonal antibody specific for asHTF as previously de-
cribed (10) was also used for staining. Myocardial staining
atterns for asHTF obtained by these two antibodies were
dentical. After incubation with primary antibody, speci-
ens were washed, incubated with an appropriate biotinyl-
ted secondary antibody (DakoCytomation, Hamburg,
ermany), and counterstained with hematoxylin (Merck,
armstadt, Germany). For detection, the Vectastain ABC
it was used according to manufacturer’s instructions (Vec-
or Laboratories, Burlingame, California).
Alternatively, immunohistochemistry was performed on
araffin-embedded tissue blocks from biopsies. Several
lides made from every block were deparaffinated overnight
y incubation with Roti-Histol (Roth, Karlsruhe, Ger-
any). After rehydration they were incubated in a trypsin
olution (1 mg/ml, Sigma, Munich, Germany) for 10 min at
7°C to enhance the penetration of the antibodies, washed
wice in Tris-buffered saline (TBS) and blocked with
vidin/Biotin Blocking Kit according to manufacturer’s 1rotocol (Vector Laboratories). The washed slides were
ncubated either with a polyclonal anti-TF antibody (1,12)
pAb-sTF, 6 g/ml) or a monoclonal anti-desmin antibody
clone D33, DakoCytomation, 2.5 g/ml) overnight at 4°C;
egative controls were performed without the use of primary
ntibodies. The detection of primary antibodies was per-
ormed as described earlier. To ensure that the counterstain-
ng with hematoxylin had no influence on the TF staining,
ontrol staining was performed without the use of hema-
oxylin.
estern blot. Samples from explanted heart tissues were
omogenized in radio-immunoprecipitation assay-buffer
upplemented with 1% protease-inhibitor cocktail (P-8340,
igma). For immunoprecipitation extracts were incubated
vernight at 4°C with a monoclonal antibody anti-TF
MabTFH clone TFE, Enzyme Research Laboratories,
outh Bend, Indiana) and afterwards precipitated with
rotein-G Plus Agarose (Santa Cruz Biotechnology, Santa
ruz, California). The precipitates were separated by
lectrophoresis on a 12% sodium dodecyl sulfate-
olyacrylamide gel (SDS-PAGE). The gels were trans-
erred to a nitrocellulose membrane (Protran BA 85,
chleicher and Schüell, Dassel, Germany), which was
locked in 5% nonfat dry milk diluted in Tris-buffered
aline. Blots were incubated for 3 h at 4°C with the primary
olyclonal antibody anti-TF (pAb-sTF, 6 g/ml). Washed
lots were incubated for 90 min with a secondary horse-
adish peroxidase-conjugated antibody (DakoCytomation).
ashed blots were subjected to the Immun-Star HRP
hemiluminescent Kit (BioRad, Hercules, California) for
etection of the immunoreactive signal by chemilumines-
ence, and the membranes were then exposed to X-ray film
Kodak X-OMAT AR, Kodak, Stuttgart, Germany). The
embranes were stripped in 100 mM glycine (pH 2.9) at
oom temperature for 60 min. The stripped blots were
locked again for 3 h and incubated with a primary
olyclonal antibody anti-asHTF (dilution 1:100, Pineda
ntikörper-Service). After the incubation, the blots were
ashed and treated as described. The membrane was
xposed to X-ray film.
rotein extraction and TF ELISA. Myocardial biopsies
ere homogenized in a glass potter containing 100 l
ce-cold radio-immunoprecipitation assay buffer, supple-
ented with 1% protease-inhibitor cocktail, incubated on
ce for 30 min and centrifuged at 10,000 g for 10 min at
°C. Total protein content of the cell lysate was measured
sing a bicinchoninic acid protein assay according to the
anufacturer’s protocol (Pierce, Rockford, Illinois). The
rotein was precipitated with acetone and afterwards resus-
ended in TBS, pH 8.5. To quantify the total TF protein
ontent (full-length TF and asHTF) in myocardial biopsies,
F ELISA was performed according to the instruction
anual (Imubind Tissue Factor ELISA Kit, American
iagnostica Inc.).
tatistical analysis. SPSS statistical software version
1.0.1 was used for statistical analysis. Nominal data were
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Altered TF Expression in Cardiomyopathy April 5, 2005:1081–9ested using chi-square and Fisher exact test. Tissue factor
RNA ratios obtained by real-time PCR were presented as
ean  SD. If more than two groups were compared,
etric normally distributed data were analyzed by one-way
nalysis of variance. If this test revealed significant differ-
nces, a Bonferroni-corrected (correction factor 3) non-
aired t test was performed. Other metric normally distrib-
ted data were expressed as mean  SD and compared by
onpaired t test. A p value 0.05 was regarded as
ignificant.
ESULTS
linical characteristics of patients and hemodynamic
arameters. The patients, from whom myocardial biopsies
ere obtained, were divided into two groups according to
he EF (EF 50% [n  37] or EF 50% [n  42]). These
roups were then subdivided into another two groups
epending on whether mRNA or protein levels were deter-
ined. The explanted heart tissues from DCM patients
ere assessed as a separate group (n  12). The left
entricular end-diastolic diameter was significantly in-
Table 2. Clinical Characteristics of the Patient
Heart Donors (Patients With DCM and Sever
With Moderate to Severely Reduced EF (50
(50%, n  19)
E
Anthropometric indices
Age (yrs)
Gender (female/male)
Echocardiographic parameters
Left ventricular end-diastolic diameter (mm)
Left ventricular variables
Ejection fraction (%)
Cardiovascular risk factors given as number of
patients with positive risk factors (%)
Hypertension
Diabetes
Lipids
Smoking
Family history
Medication given as number of
treated patients (%)
Beta-blocker
ACE inhibitors
AT1-antagonists
Diuretics
Digitalis
Amiodarone
Aspirin
Heparins
Statins
Ca-antagonists
H2 antagonists
*p  0.001 (explanted vs. EF 50%); †p  0.01 (EF 50%
(EF 50% vs. EF 50%).
ACE  angiotensin-converting enzyme; DCM  dilatereased in the DCM patients compared to those patients aith normal EF (Tables 2 and 3). There was no significant
ifference in cardiovascular risk factor profile between the
bove groups (Tables 2 and 3).
A statistical difference between the biopsied patients with
egard to the medication with beta-blocker, diuretics, and
igitalis was found as shown in Tables 2 and 3.
etection of asHTF mRNA and protein in human
yocardial tissue. AsHTF mRNA was identified in myo-
ardial biopsies and explanted hearts from DCM patients by
onventional RT-PCR. The gel electrophoresis showed not
nly the PCR product for full length TF but also an
mplification product for asHTF (Table 1A, Fig. 1). The
irect sequencing of the PCR products revealed specific
equences for full-length TF and asHTF. The asHTF
equence and protein were previously described to be
resent in human leukocytic cells but not in human myo-
ardial tissue (10,13). This is the first report about the
resence of asHTF in human adult myocardial tissues. The
uantification of TF and asHTF mRNA levels by real-time
CR in myocardial biopsies taken from the right ventricular
eptum of patients with a normal EF revealed myocardial
luded for TF Gene Expression Studies:
educed EF, n  12) and Biopsied Patients
 27) and Mildly Reduced to Normal EF
nted DCM Hearts
(n  12)
EF <50%
(n  27)
EF >50%
(n  19)
52  13 52  14 46  12
0/12 8/19 10/9
73.7  11.3* 65.8  9.1† 50.4  4.9
22.6  7.1* 26.6  8.7† 72.1  7.4
1 (8%) 12 (44%) 6 (31%)
1 (8%) 4 (14%) 3 (15%)
2 (16%) 13 (48%) 9 (47%)
2 (16%) 10 (37%) 4 (21%)
0 (0%) 3 (11%) 1 (5%)
3 (25%) 22 (81%)‡ 9 (47%)
8 (67%) 23 (85%) 11 (58%)
0 (0%) 2 (7%) 1 (5%)
12 (100%) 23 (85%)† 5 (26%)
9 (75%) 16 (59%)§ 3 (16%)
4 (33%) 1 (4%) 0 (0%)
0 (0%) 8 (30%) 7 (37%)
2 (17%) 25 (93%) 14 (74%)
0 (0%) 5 (19%) 7 (37%)
2 (17%) 0 (0%) 2 (11%)
0 (0%) 5 (19%) 5 (26%)
50%); ‡p  0.05 (EF 50% vs. EF 50%); §p  0.001
omyopathy; EF  ejection fraction; TF  tissue factor.s Inc
ely R
%, n
xpla
vs. EF
d cardisHTF expression level to be significantly lower than
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April 5, 2005:1081–9 Altered TF Expression in Cardiomyopathyyocardial TF mRNA level (13.91  105  11.20 
05 for asHTF/GAPDH ratio vs. 1.76  101  6.08 
02 for TF/GAPDH ratio; p  0.0001).
To find out whether asHTF protein was expressed in the
yocardium, western blot analysis was performed. Full
ength TF and asHTF were both detected by the polyclonal
nti-TF antibody (pAb-sTF, 6 g/ml) directed against the
xtracellular domain of the TF protein (Fig. 2, lane 1).
ehybridization of the membrane with the asHTF-specific
ntibody yielded a single protein band at 30 kDa, whereas
ull-length TF was not detected (Fig. 2, lane 2).
Immunohistochemistry showed cardiomyocytes and en-
othelial cells to be positive for asHTF in myocardial
iopsies of patients with normal EF and DCM. However,
n contrast to full-length TF, which is abundantly expressed
n the cardiomyocytes, asHTF-associated cardiomyocyte
taining appeared to be faint (Figs. 3A and 3B). There was
o difference in asHTF myocardial staining pattern com-
aring patients with normal EF and with DCM (data not
able 3. Characteristics of Patients From Whom Biopsies Have
een Taken for TF Protein: Biopsied Patients With Moderately
o Severely Reduced EF (50%, n  15) and Mildly Reduced
o Normal EF (50%, n  18)
EF <50%
(n  15)
EF >50%
(n  18)
nthropometric indices
Age (yrs) 48  14 45  15
Gender (female/male) 4/11 5/13
chocardiographic parameters
Left ventricular end-diastolic
diameter (mm)
62.9  9.1* 54.0  6.6
eft ventricular variables
Ejection fraction (%) 34.2  11.8† 58.2  9.8
ardiovascular risk factors
given as number of
patients with positive risk
factors (%)
Hypertension 7 (47%) 7 (39%)
Diabetes 1 (7%) 4 (22%)
Lipids 6 (40%) 6 (33%)
Smoking 7 (47%) 4 (22%)
Family history 3 (20%) 4 (22%)
edication given as number of
treated patients (%)
Beta-blocker 14 (93%)‡ 7 (39%)
ACE inhibitors 9 (60%) 12 (67%)
AT1-antagonists 3 (20%) 0 (0%)
Diuretics 14 (93%)§ 8 (44%)
Digitalis 5 (33%) 1 (6%)
Amiodarone 2 (13%) 2 (11%)
Aspirin 3 (20%) 4 (22%)
Heparins 14 (93%) 18 (100%)
Statins 2 (13%) 3 (17%)
Ca-antagonists 0 (0%) 1 (6%)
H2-antagonists 6 (40%) 2 (11%)
p  0.001 (EF 50% vs. EF 50%); †p  0.0001 (EF 50% vs. EF 50%);
p  0.003 (EF 50% vs. EF 50%); §p  0.004 (EF 50% vs. EF 50%).
Abbreviations as in Table 2.hown).
b
(own-regulation of TF and asHTF messenger RNA
xpression in DCM: correlation with the EF. Tissue
actor isoform specific real-time PCR was performed to
uantify the expression levels of TF and asHTF mRNA in
atients with normal EF and with DCM. The expression
evels of TF and asHTF were lower in DCM patients than
n those with normal EF. Mean and standard deviation of
F/GAPDH and asHTF/GAPDH ratios are shown in
igure 4. The myocardial TF expression in the biopsied
CM patients decreased to 60.2% (TF/GAPDH ratio 1.76
101  6.08  102 in patients with normal EF vs. 1.06
igure 1. Gel electrophoresis (1% agarose gel) of reverse transcription-
olymerase chain reaction products (human tissue factor [hTF] and
lternatively spliced human tissue factor [asHTF]) using ribonucleic acid
rom human heart biopsies. (M) 250 bp deoxyribonucleic acid ladder; (C)
o template, control; (1) explanted heart tissue (ventricular septum); (2)
uman myocardial biopsy from patient with normal cardiac function; (3)
uman myocardial biopsy from patient with severely impaired cardiac
unction.
igure 2. Western blot for tissue factor isoforms from explanted dilated
ardiomyopathy hearts. Extracts from explanted dilated cardiomyopathy
earts were immunoprecipitated with anti-human tissue factor (TF)
ntibodies directed against the TF extracellular domain. Western blots
howed both, full-length TF and alternatively spliced human tissue factor
asHTF) (lane 1), detected by a polyclonal anti-TF antibody (pAb-sTF)
irected against the extracellular domain of the TF protein. Rehybridiza-
ion of the membrane with a polyclonal antibody (asHTF), directed against
he last 29 amino acids of the unique asHTF end yielded a single protein
and at approximately 30 kDa, whereas full length TF was not detected
lane 2).
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Altered TF Expression in Cardiomyopathy April 5, 2005:1081–9101  5.26  102 in biopsied DCM patients; p 
.001). The myocardial asHTF expression in biopsied
CM patients decreased also to 51.5% (asHTF/GAPDH
atio 13.91  105  11.2  105 in patients with normal
F vs. 7.17  105  3.82  105 in biopsied DCM
atients; p  0.014). Compared with the level present in
atients with normal EF, TF mRNA levels in explanted
eart tissues from DCM patients were also decreased to
0.6% for TF (TF/GAPDH ratio 1.76  101  6.08 
02 vs. 8.91  102  2.95  102; p  0.0001) and to
2.1% for asHTF (asHTF/GAPDH ratio 13.91  105 
1.20  105 vs. 5.86  105  2.93  105; p  0.014).
he TF/GAPDH ratio and EF were positively correlated in
he patients included (r  0.504; p  0.0001; Fig. 5),
hereas the TF/GAPDH ratio and left ventricular end-
iastolic diameter (LVEDD) were negatively and only
eakly correlated (r  0.309; p  0.018). Correlations
etween the asHTF/GAPDH ratio and EF (r 0.382; p
.003; Fig. 5) as well as between asHTF/GAPDH ratio
nd LVEDD (r  0.278; p  0.04) were also weakly
ignificant.
own-regulation and cellular redistribution of TF pro-
ein in the myocardium of patients with DCM. In line
ith the mRNA results, protein quantification of total TF
ontent (full-length TF and asHTF) by ELISA revealed a
igure 4. Quantification of tissue factor (TF) expression in ventricular
eptum of explanted dilated cardiomyopathy (DCM) hearts (n  12) and
f biopsied patients with DCM (n  27) and with normal to mildly
educed ejection fraction (EF) (n  19). Data are given as mean  SD.
A) Full-length TF/glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
essenger ribonucleic acid (mRNA) ratio; (B) Alternatively spliced TF/
APDH mRNA ratio. asHTF  alternatively spliced human tissue factor.igure 3. Immunohistochemistry for tissue factor (TF), alternatively
pliced human tissue factor (asHTF), and desmin. Polyclonal rabbit
ntibodies directed against the extracellular domain of TF and the unique
-terminal end of asHTF were used for staining of the myocardial biopsies
btained from a patient with normal ejection fraction (EF) (64%) and a
atient with dilated cardiomyopathy (DCM) (21%). (A and B) Cardio-
yocytes and endothelial cells within the normal myocardium stained
ositive for asHTF. Original magnification 400. (C) Immunohistochem-
stry for desmin showed positive staining of Z-bands of the cardiomyocytes
n a patient with normal EF. The sarcolemma and Z-bands of the same
atient were also positive for TF (arrows, D). Original magnification
30. (E) The Z-bands stained also positive for desmin in the myocar-
ium of a patient with DCM. In contrary to desmin, TF staining of the
-bands was faint or completely absent in the myocardial biopsy of the
ame DCM patient (arrows, F and G). Myocardial TF was located within
he cytosol around the nucleus in DCM (arrow heads, F and G). Original
agnification 630. (H) Control for TF staining. Original magnification
30. (I) TF staining of the Z-bands of a patient with normal EF without
ematoxylin. Original magnification 630. (J) Immunohistochemistry for
F showed a diffuse staining with absence of TF-positive Z-bands. TF wasown-regulation of TF in the myocardium from patients
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aving moderate to severely impaired EF (8.8  3.0 ng/mg
otal protein (n  18) vs. 6.5  2.7 ng/mg (n  15); p 
.032; Fig. 6). Thus, the total myocardial TF protein
xpression was reduced by approximately 26%. Myocardial
F protein correlated with the EF in biopsied patients
Fig. 6B).
Immunohistochemical staining of adjacent specimens
rom myocardial biopsies with desmin and TF antibodies
evealed desmin and TF to be present in the Z-bands of the
yocardium in patients with normal EF (Figs. 3C and 3D).
issue factor was also found in the sarcolemma and inter-
alated disks of the myocardial tissue. In contrast to desmin
nd TF in hearts with normal EF, TF staining of the
-bands was faint or completely absent in DCM (Figs. 3F
nd 3G). However, the Z-bands stained positive for desmin
n myocardial biopsies of the same patients with DCM
Fig. 3E). In the myocardial biopsies from DCM patients,
F was localized in the perinuclear cytosol of the cardio-
yocytes (Figs. 3F and 3G). Thus, the myocardial speci-
ens from DCM hearts showed an altered cellular local-
zation of TF, redistributing from the Z-bands to the
erinuclear cytosol in DCM. To ensure that the counter-
taining with hematoxylin had no influence on the TF
taining, control staining was performed without the use of
ematoxylin (Figs. 3I and 3J).
Immunohistochemistry with and without hematoxylin
igure 5. Graphs demonstrate correlations between tissue factor (TF)
soform expression and ejection fraction (EF). (A) Regression line between
he messenger ribonucleic acid (mRNA) TF/glyceraldehyde-3-phosphate
ehydrogenase (GAPDH) ratio and EF (r  0.504, p  0.0001). (B)
egression line between the mRNA alternatively spliced human tissue
actor (asHTF)/GAPDH ratio and EF (r  0.382, p  0.003).ounterstaining showed both TF staining of Z-bands in iatients with normal EF (Figs. 3D and 3I), whereas an
ltered staining pattern without TF-positive Z-bands was
ound in DCM (Figs. 3E and 3J).
ISCUSSION
his study shows TF expression to be down-regulated in
he myocardium of patients with DCM. Tissue factor has
een reported to be expressed by cardiomyocytes in the
arcolemma and in the transverse part of the intercalated
isks, where it co-localizes with the cytoskeletal proteins
esmin and vinculin (4,5). The observation that TF expres-
ion correlated with the number of contact sites of cardio-
yocytes led to the hypothesis that TF might play an
mportant role in maintaining the structural integrity of the
yocardial muscle. The cytoplasmic domain of TF was
hown to interact with actin-binding protein 280 (filamin),
hereby influencing the adhesion and migration of vascular
ells (6). During postnatal maturation the increased degree
f TF immunostaining present in the intercalated disks
orrelates positively with the formation of intercardiomyo-
yte desmosomal and junctional contacts and has been
uggested to possibly influence the electromechanical func-
ion of the myocardial muscle (5,15). Lower TF levels have
een reported in structurally altered ventricular myocardium
f patients with hypertension and ventricular hypertrophy.
issue factor protein content was decreased approximately
0% in tissue extracts from the myocardium of severely
ypertrophic hearts (4). Here, we demonstrate the TF
RNA level in the ventricular septum of patients with
CM to be down-regulated to approximately 60% of that
igure 6. (A) Quantification of tissue factor (TF) protein (ng TF pro-
ein/mg total protein) from biopsied patients with dilated cardiomyopathy
n  15) and normal to mildly reduced ejection fraction (EF) (n  18).
ata are given as mean SD. (B) Correlation between TF protein and EF
r  0.423, p  0.014).n patients with normal cardiac function. Tissue factor
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Altered TF Expression in Cardiomyopathy April 5, 2005:1081–9rotein content in biopsied DCM patients was reduced by
pproximately 26%. In addition to the reduction in TF
xpression, cellular TF localization was altered, with a
islocation of TF from the Z-bands to the cytosol of the
ardiomyocytes, suggesting that the reduction and redistri-
ution of TF may contribute to myocardial dilation and
ontractile dysfunction. Whether down-regulation of TF
xpression and its cellular translocation contributes to ven-
ricular dilation and cardiac dysfunction needs to be further
lucidated. Tissue factor interacts with tissue factor pathway
nhibitor, which is expressed on cardiomyocytes (16). Of
ote, TF pathway inhibitor is known to bind heparin-
ulfated proteoglycans on various cell types, thereby con-
ributing to cell stabilization. A reduction in myocardial TF
xpression is likely to produce an overall decrease in the
umber of TF molecules localized, via its modified intra-
ellular cysteine residue (17), to lipid rafts—membrane
ormations involved in regulation of actin cytoskeleton (18).
It was previously reported (19) that the spatial expression
f membrane-bound TF corresponded to that of force-
ransmitting cytoskeletal proteins in actin-rich membrane
reas of in vitro cultured epithelial cells. In line with the
o-localization of TF with other structural proteins is the
nding that the myocardial TF expression correlated with
he ejection fraction in our patients. Data from animal
nockout experiments and clinical findings on patients with
CM suggest that defects in cytoskeletal and junctional
roteins may cause cardiac dilation, contributing to the
evelopment of cardiac pump failure (8). A reduced TF
rotein content of the left ventricular myocardium has been
escribed for patients with sepsis. It has been suspected that
he reduced TF expression by cardiomyocytes may contrib-
te to cardiac failure during sepsis (5). The reason for the
eduction of TF expression during sepsis is thus far un-
nown (20).
Differences in medication with beta-blocker, diuretics,
nd digitalis were present between our patient groups. More
atients with DCM were treated with these drugs than
atients with normal or mildly reduced EF (Tables 2 and 3).
t is not known to date whether medication with beta-
locker, diuretics, or digitalis influences TF gene expression.
owever, clinical and experimental studies suggest that
tatins and angiotensin-converting enzyme (ACE) inhibi-
ors reduce the TF expression in human monocytes (21,22)
nd endothelial cells (23,24). No differences in the fre-
uency of statin or ACE inhibitor administration were
bserved between our patient groups. Thus, we can exclude
hat a difference in TF gene expression between our patients
roups is related to differences in therapy with statins or
CE. Nevertheless, it should be emphasized that the
echanisms and regulation pathways of TF gene expression
n cardiomyocytes are poorly understood.
Here we also report the presence of asHTF in cardiomy-
cytes and endothelial cells of the human myocardium.
lternatively spliced human tissue factor has been demon-trated to circulate in the blood of healthy human beings,eing able to induce factor Xa generation (10). Acellular TF
as also been reported to be present in blood of patients
ndergoing coronary artery bypass grafting (25). In these
atients, the fluid-phase form of TF failed to support
hrombin generation, whereas full-length TF present in
icroparticles in the blood promoted thrombin generation
25). Acellular TF may bind to TF pathway inhibitor,
hereby modulating blood thrombogenicity. Leukocytes
ave been suggested as a source for asHTF in blood, as
hese cells are able to synthesize asHTF (10). Whether
ndothelial cells contribute to the presence of asHTF in the
lood under pathologic conditions is unknown. In compar-
son with full-length TF, only a limited amount of asHTF
rotein was found to be present in the right ventricular
eptum. The quantification of myocardial TF expression
howed that both full-length TF and asHTF were reduced
n patients with DCM. In addition, the expression of
ull-length TF in myocardial tissues correlated well with
yocardial contractility, pointing to an association of trans-
embrane TF expression and myocardial function. A phys-
ological role for asHTF, which is a soluble protein, has thus
ar not been identified for the heart. In addition, the
orrelation between the soluble isoform of TF and EF was
nly weak. Whether asHTF is expressed to a larger extent
ithin the myocard of the atrium and/or the reduction of
sHTF in DCM contributes to dysfunction of the myocar-
ial muscle remains a subject of further investigation.
In summary, the TF expression was down-regulated in
he myocardium of DCM patients. The reduction in TF
xpression and its dislocation from the Z-bands into the
ytosol of the cardiomyocytes may adversely affect the
ell-to-cell contact stability, thereby contributing to ventric-
lar dilation and cardiac dysfunction in DCM.
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